Theriva Biologics, Inc. · AMEX:TOVX
Theriva Biologics — Investor Presentation (April 2024)
46 slides from Theriva Biologics's investor presentation, April 2024
Slide 1: Corporate Overview
Corporate Overview April 2024
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "antici
Slide 3: Overview
OVERVIEW • Theriva Biologics is developing unique oncolytic viruses optimized for systemic administration Financial Snapshot Exchange NYSE American • VCN-01 is undergoing a Phase 2b clinical trial in Ticker TOVX first-line metastatic pancreatic cancer in Cash (12/31/2023) $23.2M combination with SoC
Slide 4: Theriva Pipeline
THERIVA PIPELINE Candidate Target Pre-IND Phase 1 Phase 2 Collaborators Status* Pancreatic Cancer (IV) with Phase 2 Study On-going gemcitabine/nab-paclitaxel (ODD EU, US) Phase1 Study On-going Retinoblastoma (IVit) (ODD US) VCN-01 Selective, Stroma Degrading OV Phase 1 Treatment Complete HNSCC (IV)
Slide 5: VCN-01 Is a Uniquely Engineered Human Adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 Access primary and metastatic lesions Systemic High dose, highly replicating Replicates only in tumor cells Selective Liver detargeted Expresses PH20 (hyaluronidase) Stroma Degrading after viral replication cycle -- RGDK PH20 in blood is a biomarker
Slide 6: VCN-01 Is a Uniquely Engineered Human Adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 SYSTEMIC administration enables VCN-01 access to SELECTIVE replication at very high levels lyses tumor 1 primary tumor and metastases and detargets the liver 2 cells directly without harming healthy tissues VCN-01 Tumor Surrounded by STROMA Cancer A
Slide 7: VCN-01 Designed to Have Multiple Anti-Tumor Actions
VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS STROMA degradation by PH20 facilitates tumor access IMMUNOGENIC actions of VCN-01 turn “cold” tumors 3 and destruction by coadministered cancer therapies 4 “hot” and elicit an anti-tumor immune response PH20 nab-paclitaxel PH20 PH20 PH20 gemcitabin
Slide 8: VCN-01 Compared to Other Oncolytic Viruses
VCN-01 COMPARED TO OTHER ONCOLYTIC VIRUSES THERIVA ONCOLYTICS COMPANY CG ONCOLOGY GENELUX REPLIMMUNE BIOLOGICS BIOTECH Ticker NYSE MKT: TOVX NASDAQ: CGON NASDAQ: GNLX NASDAQ:ONCY NASDAQ: REPL Product VCN-01 CG0070 Olvi-Vec Pelareorep RP1, RP2 Virus Adenovirus 5 Adenovirus 5 Vaccinia Reovirus Herpes
Slide 9: Clinical Data Support VCN-01 Mode-of-Action
CLINICAL DATA SUPPORT VCN-01 MODE-OF-ACTION Remodels the tumor matrix and turns “cold” tumors “hot” Built-in biomarker: PH20 levels in patient sera Immune markers upregulated in indicate sustained VCN-01 activity in tumors biopsies of hepatic metastases VCN-01 1.0x10¹³ vp (Arms I, II, III) CD8+ lymp
Slide 10: VCN-01 Extensive Clinical Program
VCN-01 EXTENSIVE CLINICAL PROGRAM 116 patients treated to date in multiple indications and combinations Rb – IVit (alone)* COLORECTAL – IV BRAIN TUMORS – IV (alone)* (alone) PANCREATIC - IV (+ Gemcitabine / Abraxane®) HEAD & NECK – IV (alone) HEAD & NECK – IV Phase 1 and ongoing Phase 2b (+ Durvalum
Slide 11: VCN-01 Lead Indication Pancreatic Cancer
VCN-01 LEAD INDICATION PANCREATIC CANCER Highly fatal cancer protected by dense tumor stroma • Orphan disease with the highest mortality of all solid tumors • Median survival 8-11 months for metastatic disease¹ • USA est. 62,210 new cases and 49,830 deaths in 2022²,³ • Hyaluronic acid in stroma is a
Slide 12: VCN-01 Favorable Outcomes in Phase 1 Trial
VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study (NCT02045602) ✓ Single IV doses of VCN-01 alone or with standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel (Abraxane®) ✓ Evaluate safety and tolerability, recommended Phase 2 dose ¹Single dose of VC
Slide 13: VCN-01 Favorable Outcomes in Phase 1 Trial
VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study (NCT02045602) OUTCOME VCN-01 DOSE, virus particles (n)¹ SoC ALONE² RELATED AEs IN ≥1 PATIENT¹ CTCAE SEVERITY Sequential Regimen 3.3x10¹² (6) 1.0x10¹³ (6) Combined (12) Phase 3 (431) VCN-01 Combined, Sequential
Slide 14: VIRAGE Phase 2b Clinical Trial in PDAC
VIRAGE PHASE 2B CLINICAL TRIAL in PDAC Multicenter, open-label, randomized, controlled trial (NCT05673811) • Study on-going in patients with first-line metastatic pancreatic ductal adenocarcinoma (PDAC) • Up to 92 patients to be enrolled at sites in Spain and the USA • Randomized 1:1 to receive gemc
Slide 15: VIRAGE Phase 2 Clinical Trial – Differentiators
VIRAGE PHASE 2 CLINICAL TRIAL – DIFFERENTIATORS ✓ First-line treatment of metastatic PDAC patients ✓ Direct comparison with standard-of-care chemotherapy in the same trial ✓ Repeated dosing of VCN-01 may improve treatment outcomes ✓ Open label provides real-time opportunity to review emerging VCN-01
Slide 16: VCN-01 Development in Pancreatic Cancer
VCN-01 DEVELOPMENT IN PANCREATIC CANCER • Project complete enrollment into the VIRAGE Study H1 2024 • First DMC safety review completed Q1 2024 • No safety concerns were raised and no protocol amendments were requested • Potential interim data analysis H2 2024 • Opportunity to discuss pivotal study
Slide 17: VCN-01 in Head & Neck Cancer
@ Theriva VCN-01 IN HEAD & NECK CANCER
Slide 18: VCN-01 IV + Anti-PD-L1 Phase 1 Trial in HNSCC
VCN-01 IV + ANTI-PD-L1 PHASE 1 TRIAL in HNSCC Multicenter, open-label, dose escalation study (NCT03799744) ✓ Single IV doses of VCN-01 combined with anti-PD-L1 ✓ Patients with metastatic squamous cell carcinoma of the head & neck previously REFRACTORY to anti-PD(L)1 treatment (R/M HNSCC) ✓ Evaluate
Slide 19: Extended Survival with VCN-01 + Durvalumab
EXTENDED SURVIVAL with VCN-01+DURVALUMAB Survival correlated with PD-L1 upregulation after VCN-01 treatment • Higher than expected survival (OS) Overall Survival vs CPS in Biopsies at Day 8 despite previous anti-PD(L)1 failure Spearman r = 0.7676 P (2-tailed) = 0.0050 Regimen Median OS (95% CI), mos
Slide 20: VCN-01 May Sensitize Patients to Subsequent Therapy
VCN-01 MAY SENSITIZE PATIENTS TO SUBSEQUENT THERAPY Patients responded to subsequent chemotherapy after progressing with VCN-01 + durvalumab ICI Treatment 1st Line after 2nd Line after Current Trial Progression (Pre-trial) Current Trial Current Trial ARM Median OS post-1st ICI ORR Median PFS Median
Slide 21: VCN-01 Findings in R/M HNSCC
VCN-01 FINDINGS in R/M HNSCC Data support VCN-01 MOA and immune enhancing effects • VCN-01 has an acceptable safety profile when administered prior to durvalumab (Imfinzi®) • VCN-01 reaches tumors, has sustained replication and PH20 expression • VCN-01 treatment led to downregulation of tumor matrix
Slide 22: VCN-01 in Retinoblastoma
@ Theriva VCN-01 IN RETINOBLASTOMA
Slide 23: Retinoblastoma, a Rare Pediatric Malignancy
RETINOBLASTOMA, A RARE PEDIATRIC MALIGNANCY • Retinoblastoma (Rb) is an orphan indication that accounts for ~2-3% of all childhood cancers¹ • 200-300 cases each year in the USA, EU²-⁴ • VCN-01 selectivity enables development as an intravitreal treatment for Rb patients • VCN-01 could be used in comb
Slide 24: VCN-01 in Retinoblastoma
VCN-01 IN RETINOBLASTOMA • On-going single center, open-label, dose escalation study of intravitreal (IVit) VCN-01¹-³ Promising Results in Patients Treated • Children aged 1-12 years (n=9) with High Dose VCN-01 • Retinoblastoma that is recurrent or refractory to chemotherapy Reduced number and size
Slide 25: Interim Safety Data for Intravitreal VCN-01
INTERIM SAFETY DATA FOR INTRAVITREAL VCN-01 Two Intravitreal VCN-01 Doses of 2.0x10⁹ or 2.0x1010 vp per eye¹ Adverse Reaction Pts All Grades Grade ≥3 Stable Electroretinographic Signals CTCAE grade N n % n % Uveitis 6 2 33% 2 33% Eye oedema 6 1 17% 0 0% Conjunctival hyperemia 6 1 17% 0 0% Eye inflam
Slide 26: VCN-01 Development in Retinoblastoma
VCN-01 DEVELOPMENT IN RETINOBLASTOMA • Phase 1 ISS to Complete in H1 2024 • Enrollment completed and last patients in the follow-up period • Initial data demonstrate acceptable safety and one durable complete response • Developing a clinical protocol for an open-label, multinational study • Retinobl
Slide 27: Next Generation OV Discovery Platform
NEXT GENERATION OV DISCOVERY PLATFORM
Slide 28: Albumin Shield to Enhance OV Systemic Delivery
ALBUMIN SHIELD to ENHANCE OV SYSTEMIC DELIVERY • Albumin Shield technology protects OVs as they OV Parent oncolytic virus (OV) susceptible to travel to tumors after systemic administration¹,² neutralizing antibodies • Albumin Shield modified OVs bind albumin in the patient’s blood to form a protecti
Slide 29: Theriva OV Pipeline Discovery and Development
THERIVA OV PIPELINE DISCOVERY AND DEVELOPMENT Advancing founders’ decade of world leading OV innovation Common Features Product Specific Features Clinically-tested Adenovirus Expressing PH20 VCN-11 Hyaluronidase alone Hyaluronidase to Degrade Stroma + VCN-12 Hyaluronidase + Toxins Albumin Shield To
Slide 30: Summary
@ Theriva SUMMARY
Slide 31: Theriva OV Portfolio Highlights
THERIVA OV PORTFOLIO HIGHLIGHTS Unique MOA enables multiple indications and combinations • Highly differentiated OV designed to have multiple antitumor effects • Systemic administration, selective tumor replication, stroma degradation • Designed to increases cell lysis, tumor immunogenicity, and tum
Slide 32: Achievements and Projected Milestones
ACHIEVEMENTS AND PROJECTED MILESTONES • VCN-01 PDAC Potential FDA and EMA discussions of pivotal design • VCN-01 PDAC • VCN-01 RETINOBLASTOMA Potential interim data analysis SIOP presentation (Phase 1)³ (Q3/Q4) Finalize Phase 2 study design • VCN-01 PDAC • VCN OV DISCOVERY • VCN-01 + CAR-T Phase 2 e
Slide 33: Financial and Investment Goals
FINANCIAL AND INVESTMENT GOALS • Immediate Goals • Augment share register with additional sophisticated institutional investors • Establish a realistic share price/valuation to facilitate financial options • External validation through a funded discovery or development partnership • Mid- to Longer-T
Slide 34: Seasoned Leadership Team
SEASONED LEADERSHIP TEAM Steven Shallcross Manel Cascalló PhD Vince Wacher PhD Chief Executive Officer, Chief General Director, EU Subsidiary Head Corporate Development Financial Officer Expertise in oncolytic adenovirus Nearly 30 years leading corporate Served as the Company’s CEO since clinical de
Slide 35: Appendix
@ Theriva APPENDIX
Slide 36: Intellectual Property
INTELLECTUAL PROPERTY Hyaluronidase OV Albumin Shield Oral β-Lactamase Oral IAP VCN-01, VCN-11 VCN-11, Discovery SYN-004, -006, -007 SYN-020 Composition of Matter Composition of Matter Composition of Matter Manufacturing Know-how (exp 2030) (exp 2034) (exp 2031-5) (Trade Secret) Methods of Use and M
Slide 37: Extensive VCN-01 Phase 1 Clinical Experience
EXTENSIVE VCN-01 PHASE 1 CLINICAL EXPERIENCE 87 Patients Treated in Diverse Cancer Indications Phas Rout Location Indication Co-therapy Status Registry e e Multicenter (ESP) 1 Part I: None Part I: Solid tumor Parts II,III: Gemcitabine + IV Complete¹ NCT02045602 Part II, III: PDAC nab-Paclitaxel Gemc
Slide 38: Most Common IV VCN-01 Related AEs
MOST COMMON IV VCN-01 RELATED AEs [NCT02045602] ADVERSE EVENTS¹ Part I (Alone, n=16) Part II (Concomitant, 12)² Part III (Sequential, 14)³ Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3* Grade 1-2 Grade ≥3 Febrile neutropenia - - - 2 (16.7%) - - Neutropenia/Neutrophil count decreased 2 (12.5%) - 1 ( 8.3%) 1
Slide 39: Expansion Opportunities for VCN-01 in PDAC
EXPANSION OPPORTUNITIES for VCN-01 in PDAC Alternate treatment lines and new chemotherapy combinations Borderline Locally Advanced Metastatic / Recurrent Status Resectable Resectable (unresectable) (unresectable) Staging Stage I Stage II Stage III Stage IV Radiotherapy if increases resection margins
Slide 40: AE Profile for the Combination of VCN-01 and Durvalumab
AE PROFILE FOR THE COMBINATION OF VCN-01 AND DURVALUMAB Most common AEs related to IV VCN-01 [NCT03799744] Arm I - Concomitant Arm II - Sequential Arm II - Sequential Adverse Reactions (Dose 3,3E12 , n=6)² (Dose 3,3E12 , n=6)³ (Dose 1E13 , n=8)³ CTCAE Grade Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grad
Slide 41: VCN-01 Induces Transcriptomic Changes in Tumor Microenvironment
VCN-01 INDUCES TRANSCRIPTOMIC CHANGES in TUMOR MICROENVIRONMENT RNAseq Analysis in Clinical Samples from HNSCC Patients [NCT03799744] Principal Component Analysis1 Most significant Reactome and KEGG pathways in GSEA (Gene Set Enrichment Analysis) 1 including all the Pre- and Post-treatment samples a
Slide 42: Theriva Oncolytic Viruses Key Publications
THERIVA ONCOLYTIC VIRUSES KEY PUBLICATIONS Bayo-Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 87:2487–2495 Bazan-Peregrino M et al. (2021) VCN-01 disrupts
Slide 43: Pancreatic Cancer References
PANCREATIC CANCER REFERENCES DESCRIPTION, CLASSIFICATION, STAGING, STROMA Balachandran VP et al. (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056-72 Christenson ES et al. (2020) Current and emerging therapies for patients wit
Slide 44: Retinoblastoma (Rb) References
RETINOBLASTOMA (Rb) REFERENCES DESCRIPTION, CLASSIFICATION, STAGING American Academy of Ophthalmology. EyeWiki®. Retinoblastoma. https://eyewiki.org/Retinoblastoma American Cancer Society. Key statistics for retinoblastoma. https://www.cancer.org/cancer/retinoblastoma/about/key-statistics.html Cantu
Slide 45: OV Company References
OV COMPANY REFERENCES CG Oncology CG0070 (cretostimogene grenadenorepvec) https://cgoncology.com Ramesh N et al. (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12:305 Svatek R
Slide 46: OV Company References
OV COMPANY REFERENCES Oncolytics Biotech: Pelareorep (formerly Reolysin®) https://oncolyticsbiotech.com Arnold D et al. Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Theriva Biologics — Investor Presentation (April 2024) on 6ix